JP6875373B2 - ナノ粒子凍結乾燥形態のための組成物および方法 - Google Patents

ナノ粒子凍結乾燥形態のための組成物および方法 Download PDF

Info

Publication number
JP6875373B2
JP6875373B2 JP2018503253A JP2018503253A JP6875373B2 JP 6875373 B2 JP6875373 B2 JP 6875373B2 JP 2018503253 A JP2018503253 A JP 2018503253A JP 2018503253 A JP2018503253 A JP 2018503253A JP 6875373 B2 JP6875373 B2 JP 6875373B2
Authority
JP
Japan
Prior art keywords
compound
cyclodextrin
cholesterol
composition
hydroxyalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018503253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521083A (ja
JP2018521083A5 (cg-RX-API-DMAC7.html
Inventor
イン，ウェンビン
アダミ，ロジャー
ワン，ユーウエイ
イン，ハイキン
ワン，リーピン
リウ，ドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of JP2018521083A publication Critical patent/JP2018521083A/ja
Publication of JP2018521083A5 publication Critical patent/JP2018521083A5/ja
Priority to JP2021072339A priority Critical patent/JP7268079B2/ja
Application granted granted Critical
Publication of JP6875373B2 publication Critical patent/JP6875373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018503253A 2015-07-22 2016-07-22 ナノ粒子凍結乾燥形態のための組成物および方法 Active JP6875373B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021072339A JP7268079B2 (ja) 2015-07-22 2021-04-22 ナノ粒子凍結乾燥形態のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
US62/195,356 2015-07-22
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021072339A Division JP7268079B2 (ja) 2015-07-22 2021-04-22 ナノ粒子凍結乾燥形態のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018521083A JP2018521083A (ja) 2018-08-02
JP2018521083A5 JP2018521083A5 (cg-RX-API-DMAC7.html) 2019-08-29
JP6875373B2 true JP6875373B2 (ja) 2021-05-26

Family

ID=57834582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018503253A Active JP6875373B2 (ja) 2015-07-22 2016-07-22 ナノ粒子凍結乾燥形態のための組成物および方法
JP2021072339A Active JP7268079B2 (ja) 2015-07-22 2021-04-22 ナノ粒子凍結乾燥形態のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021072339A Active JP7268079B2 (ja) 2015-07-22 2021-04-22 ナノ粒子凍結乾燥形態のための組成物および方法

Country Status (23)

Country Link
US (3) US10300018B2 (cg-RX-API-DMAC7.html)
EP (1) EP3324932B1 (cg-RX-API-DMAC7.html)
JP (2) JP6875373B2 (cg-RX-API-DMAC7.html)
KR (1) KR102716928B1 (cg-RX-API-DMAC7.html)
CN (2) CN113679689B (cg-RX-API-DMAC7.html)
AU (1) AU2016297153B2 (cg-RX-API-DMAC7.html)
CA (1) CA2992849C (cg-RX-API-DMAC7.html)
CY (1) CY1123984T1 (cg-RX-API-DMAC7.html)
DK (1) DK3324932T3 (cg-RX-API-DMAC7.html)
EA (1) EA035761B1 (cg-RX-API-DMAC7.html)
ES (1) ES2862191T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210523T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053990T2 (cg-RX-API-DMAC7.html)
IL (2) IL288342B2 (cg-RX-API-DMAC7.html)
LT (1) LT3324932T (cg-RX-API-DMAC7.html)
MX (1) MX373982B (cg-RX-API-DMAC7.html)
PL (1) PL3324932T3 (cg-RX-API-DMAC7.html)
PT (1) PT3324932T (cg-RX-API-DMAC7.html)
RS (1) RS61607B1 (cg-RX-API-DMAC7.html)
SI (1) SI3324932T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100196T1 (cg-RX-API-DMAC7.html)
TW (1) TWI732773B (cg-RX-API-DMAC7.html)
WO (1) WO2017015552A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms
CA3085694A1 (en) 2017-12-12 2019-06-20 Lead Biotherapeutics Ltd. Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
AU2019347774A1 (en) 2018-09-28 2021-03-25 Nutcracker Therapeutics, Inc. Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery
EP4365289A3 (en) * 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
JP7597334B2 (ja) * 2019-09-26 2024-12-10 日油株式会社 脂質ナノ粒子の凍結乾燥組成物
AU2021228236A1 (en) * 2020-02-28 2022-10-06 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
WO2021216541A1 (en) * 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
IL300519A (en) * 2020-08-14 2023-04-01 Arcturus Therapeutics Inc Method for lyophilization of lipid nanoparticles
WO2022071582A1 (ja) 2020-10-02 2022-04-07 国立大学法人北海道大学 脂質ナノ粒子
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
WO2025015189A1 (en) * 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
PT2277551E (pt) * 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
AU2004251680B2 (en) * 2003-06-04 2010-02-18 Georgetown University Method for improving stability and shelf-life of liposome complexes
US20060110441A1 (en) 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
JP2008520600A (ja) * 2004-11-19 2008-06-19 ノヴォソム アクチェンゲゼルシャフト 局所投与のための医薬組成物におけるまたはそれに関する改善
JP5334170B2 (ja) * 2007-02-09 2013-11-06 国立大学法人 奈良先端科学技術大学院大学 Ｃ７０含有リポソームおよびその製造方法、並びにその利用
EP2509634B1 (en) * 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) * 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
CA3198966A1 (en) 2011-06-08 2012-12-13 Translate Bio, Inc. Cleavable lipids
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
RU2648753C2 (ru) 2011-10-21 2018-03-28 Селатор Фармасьютикалз Инк. Лиофилизированные липосомы
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
EP3673898A1 (en) 2011-11-04 2020-07-01 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
KR102123129B1 (ko) 2012-03-28 2020-06-15 디스커버리 라보라토리스, 인크. 합성 리포솜 폐 계면활성제의 동결건조
HK1206644A1 (en) * 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
CA2876148C (en) 2012-06-08 2021-01-12 Nitto Denko Corporation Lipids for therapeutic agent delivery formulations
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
IL288342B2 (en) * 2015-07-22 2024-02-01 Nitto Denko Corp Compositions and methods for nanoparticle lyophile forms

Also Published As

Publication number Publication date
IL257029A (en) 2018-03-29
US20190231695A1 (en) 2019-08-01
PT3324932T (pt) 2021-04-06
AU2016297153A1 (en) 2018-03-01
CN108024957B (zh) 2021-08-24
US20170020819A1 (en) 2017-01-26
ES2862191T3 (es) 2021-10-07
KR102716928B1 (ko) 2024-10-11
US10300018B2 (en) 2019-05-28
EA201890367A1 (ru) 2018-06-29
EP3324932B1 (en) 2021-03-10
RS61607B1 (sr) 2021-04-29
IL257029B (en) 2021-12-01
MX2018000891A (es) 2018-06-11
JP2021119161A (ja) 2021-08-12
LT3324932T (lt) 2021-04-26
IL288342B2 (en) 2024-02-01
CY1123984T1 (el) 2022-05-27
SI3324932T1 (sl) 2021-07-30
MX373982B (es) 2020-07-15
TWI732773B (zh) 2021-07-11
JP2018521083A (ja) 2018-08-02
IL288342A (en) 2022-01-01
EP3324932A1 (en) 2018-05-30
SMT202100196T1 (it) 2021-05-07
WO2017015552A1 (en) 2017-01-26
EA035761B1 (ru) 2020-08-06
US12311055B2 (en) 2025-05-27
US11737982B2 (en) 2023-08-29
US20240000710A1 (en) 2024-01-04
PL3324932T3 (pl) 2021-07-05
IL288342B1 (en) 2023-10-01
CA2992849C (en) 2023-06-13
AU2016297153B2 (en) 2021-02-25
DK3324932T3 (da) 2021-04-06
EP3324932A4 (en) 2019-03-06
HUE053990T2 (hu) 2021-08-30
TW201717914A (zh) 2017-06-01
CN113679689B (zh) 2023-09-01
HRP20210523T1 (hr) 2021-05-14
KR20180030698A (ko) 2018-03-23
JP7268079B2 (ja) 2023-05-02
CN108024957A (zh) 2018-05-11
CA2992849A1 (en) 2017-01-26
BR112018001178A2 (pt) 2018-09-11
CN113679689A (zh) 2021-11-23

Similar Documents

Publication Publication Date Title
JP6875373B2 (ja) ナノ粒子凍結乾燥形態のための組成物および方法
ES2251134T3 (es) Uso de complejos entre liposomas cationicos y polidesoxirribonucleotidos como medicamentos.
CN114409554A (zh) 一种新型阳离子脂质化合物及其组合物和用途
CN116531340A (zh) mRNA脂质纳米颗粒的冻干制剂及其制备方法
JP7164233B2 (ja) 高分子化薬物含有医薬組成物
US20050260260A1 (en) Liposome compositions for the delivery of macromolecules
CA2991655A1 (en) Formulations for improving the efficacy of hydrophobic drugs
US9457102B2 (en) Therapeutic muscular dystrophy drug having bubble liposome loaded with morpholino as active ingredient
JP7204744B2 (ja) ｃ（ＲＧＤ－ＡＣＰ－Ｋ）修飾血中滞留型リポソーム
JP7667077B2 (ja) Ｒｎａ干渉送達製剤及び悪性腫瘍のための方法
CN105616354A (zh) 一种新藤黄酸脂质体注射剂及其制备方法
JP2024528714A (ja) 分解からの生物学的物質種の保護
BR112018001178B1 (pt) Composição, processo de produção de liófilo sólido, liófilo sólido, processo de preparação de um medicamento, medicamento e processo de preparação de um medicamento de ácido nucleico
CA3157379A1 (en) Delivery system complexes comprising a precipitate of an active agent and methods of use
AU2018328532A1 (en) Pharmaceutical composition of docetaxel conjugate and preparation method
CN107375212B (zh) 一种托匹司他脂质体制剂及其制备方法
EA005308B1 (ru) Препараты эстрамустинфосфата для парентерального применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210422

R150 Certificate of patent or registration of utility model

Ref document number: 6875373

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE

Ref document number: 6875373

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250